Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals, Inc. (AVIR)
:AVIR
Earnings Data
Report Date
Mar 03, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.49Last Year’s EPS
-0.4Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the HCV Phase III program, strong financial health, and promising new research findings. Challenges include an increase in R&D expenses and a decrease in interest income. Overall, the sentiment is predominantly positive due to the outweighing highlights.Company Guidance
HCV Phase III Program Progress
The global Phase III program for HCV is on track with patient enrollment for the North American trial, CBEYOND, expected to complete next month. Top-line results are anticipated in mid-2026. The Sea Forward trial, outside North America, is also progressing with enrollment completion expected mid-2026 and results by late 2026.
Strong Financial Position
Atea Pharmaceuticals maintains a strong balance sheet with approximately $329.3 million in cash, cash equivalents, and marketable securities, providing financial runway through 2027.
New Research and Pipeline Expansion
Announced new research findings on bemifovir's unique dual mechanism of action against HCV. Additionally, the antiviral hepatitis pipeline is expanding to include hepatitis E, targeting a major unmet medical need in immunocompromised patients.
Positive Data from Liver Meeting 2025
Presented multiple datasets reinforcing the clinical profile of the bemifovir and riluzole regimen for HCV, including predictions of a cure time of seven to eight weeks and no impact from NS5A resistant variants at baseline.
No Drug-Drug Interaction with Acid-Reducing Therapy
Recent data shows no interaction with famotidine and prior data showed no interaction with proton pump inhibitors, a significant differentiator from Epclusa.
AVIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AVIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $3.50 | $3.06 | -12.57% |
Aug 07, 2025 | $3.46 | $3.38 | -2.31% |
May 12, 2025 | $2.96 | $2.63 | -11.15% |
Mar 06, 2025 | $3.00 | $2.99 | -0.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Atea Pharmaceuticals, Inc. (AVIR) report earnings?
Atea Pharmaceuticals, Inc. (AVIR) is schdueled to report earning on Mar 03, 2026, After Close (Confirmed).
What is Atea Pharmaceuticals, Inc. (AVIR) earnings time?
Atea Pharmaceuticals, Inc. (AVIR) earnings time is at Mar 03, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVIR EPS forecast?
AVIR EPS forecast for the fiscal quarter 2025 (Q4) is -0.49.